Podcast #52 · 24 Mar 2026
Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer
- Breast Oncology
- Medical Oncology
- HER2-Positive Metastatic Breast Cancer
- Breast Cancer
- Clinical Trials
- Interstitial Lung Disease (ILD)
- Antibody-Drug Conjugates (ADCs)
- Pulmonology
Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings.